Brief: EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints

EyePoint

05/02/2025 12:40

Feb 5 (Reuters) - EyePoint Pharmaceuticals Inc  EYPT.O :
    * EYEPOINT ANNOUNCES POSITIVE SIX-MONTH RESULTS FOR THE
PHASE 2
VERONA CLINICAL TRIAL OF DURAVYU™ FOR DIABETIC MACULAR EDEMA
MEETING PRIMARY AND SECONDARY ENDPOINTS
    * EYEPOINT PHARMACEUTICALS INC - PRIMARY ENDPOINT ACHIEVED
BY BOTH
DURAVYU DOSES
    * EYEPOINT PHARMACEUTICALS INC: PHASE 3 NON-INFERIORITY
PIVOTAL
PROGRAM INITIATION ANTICIPATED BY END OF 2025 -
    * EYEPOINT PHARMACEUTICALS INC - PHASE 3 NON-INFERIORITY
PROGRAM
INITIATION EXPECTED BY END OF 2025
    * EYEPOINT PHARMACEUTICALS INC - NO DURAVYU-RELATED OCULAR
OR
SYSTEMIC SAES REPORTED

Source text:  ID:nGNX9wF18z 
Further company coverage:  EYPT.O 

 ((Reuters.Briefs@thomsonreuters.com;))